Summary

Persistence Market Research has recently released a comprehensive report on the worldwide Induced Pluripotent Stem Cells Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• Induced Pluripotent Stem Cells Market Size (2025E):US$ 2,051.9 Mn
• Projected Market Value (2032F): US$ 3,360.0 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 7.3%

Induced Pluripotent Stem Cells Market – Report Scope:

Induced pluripotent stem cells (iPSCs) are adult somatic cells that have been genetically reprogrammed to an embryonic stem cell–like state, enabling them to differentiate into various cell types. These cells are widely utilized in regenerative medicine, disease modeling, drug discovery, and toxicity testing due to their self-renewal capability and pluripotency. The induced pluripotent stem cells market serves academic and research institutes, biotechnology and pharmaceutical companies, and contract research organizations. Growing interest in personalized medicine, advancements in cell reprogramming techniques, and increasing use of iPSCs as alternatives to embryonic stem cells are contributing significantly to market growth.

Market Growth Drivers:

The global induced pluripotent stem cells market is driven by rising investments in stem cell research and the increasing demand for advanced disease modeling platforms in drug development. The growing prevalence of chronic and degenerative diseases, such as neurological disorders, cardiovascular diseases, and diabetes, has accelerated the adoption of iPSC-based research solutions. Technological advancements in genome editing tools, including CRISPR-Cas9, along with improved differentiation protocols, have enhanced the efficiency and reliability of iPSCs. Furthermore, expanding applications of iPSCs in toxicity testing and personalized drug screening are supporting sustained market growth.

Market Restraints:

Despite favorable growth prospects, the induced pluripotent stem cells market faces challenges related to high production costs, technical complexity, and variability in cell quality. The development, maintenance, and differentiation of iPSCs require specialized infrastructure and skilled personnel, which can limit adoption among smaller research institutions. Regulatory uncertainties associated with clinical applications and long development timelines for cell-based therapies further restrain market expansion. Ensuring standardization, scalability, and regulatory compliance remains a key challenge for industry participants.

Market Opportunities:

The induced pluripotent stem cells market presents significant growth opportunities driven by advancements in regenerative medicine and precision healthcare. iPSC-based therapies hold strong potential for treating previously incurable diseases, creating new avenues for clinical applications. Increasing collaboration between academic institutions, biotechnology companies, and pharmaceutical firms is accelerating innovation and commercialization. Additionally, emerging markets with expanding biomedical research funding and supportive government initiatives offer attractive opportunities for market players to expand their global footprint.

Key Questions Answered in the Report:

• What are the major factors driving the growth of the induced pluripotent stem cells market worldwide?
• Which applications and end-user segments are fueling the adoption of iPSC technologies?
• How are technological advancements influencing innovation and competition in the iPSC market?
• Who are the key players operating in the induced pluripotent stem cells market, and what strategies are they adopting?
• What are the emerging trends and future growth prospects of the global induced pluripotent stem cells market?

Competitive Intelligence and Business Strategy:

Leading companies in the global induced pluripotent stem cells market focus on research and development, strategic collaborations, and expansion of product portfolios to strengthen their competitive position. Market players are investing in high-quality iPSC lines, advanced reprogramming technologies, and scalable manufacturing processes to meet growing research and therapeutic demand. Partnerships with academic research centers and pharmaceutical companies support technology validation and accelerate translational research. Continuous innovation and compliance with evolving regulatory frameworks remain central to sustaining competitiveness in the dynamic iPSC landscape.

Key Companies Profiled:

• Lonza Group AG
• Thermo Fisher Scientific, Inc.
• FUJIFILM Cellular Dynamics, Inc.
• Takara Bio Inc.
• REPROCELL Inc.
• Merck KGaA
• Fate Therapeutics
• Evotec SE
• Applied StemCell, Inc.

Global Induced Pluripotent Stem Cells Market Segmentation

By Cell Type
• Hepatocytes
• Fibroblasts
• Keratinocytes
• Neurons

By Application
• Drug Development
• Regenerative Medicine
• Toxicity Testing

By End User
• Academic and Research Institutes
• Biotechnology Companies

By Region
• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Induced Pluripotent Stem Cells Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025 - 2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Product Adoption Analysis
3.2. Diseases Epidemiology
3.3. In-Vivo Modelling for Neurological Disorder
3.4. Pipeline Assessment
3.5. Regulatory Landscape
3.6. Value Chain Analysis
3.7. Key Deals and Mergers
3.8. PESTLE Analysis
3.9. Porter’s Five Force Analysis
4. Global Induced Pluripotent Stem Cells Market Outlook
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
4.2.2. Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Induced Pluripotent Stem Cells Market Outlook: Cell Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Cell Type, 2019-2024
4.3.3. Market Size (US$ Mn) Analysis and Forecast, By Cell Type, 2025-2032
4.3.3.1. Hepatocytes
4.3.3.2. Fibroblasts
4.3.3.3. Keratinocytes
4.3.3.4. Neurons
4.3.3.5. Others
4.3.4. Market Attractiveness Analysis: Cell Type
4.4. Global Induced Pluripotent Stem Cells Market Outlook: Application
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2024
4.4.3. Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
4.4.3.1. Drug Development
4.4.3.2. Regenerative Medicine
4.4.3.3. Toxicity Testing
4.4.4. Market Attractiveness Analysis: Application
4.5. Global Induced Pluripotent Stem Cells Market Outlook: End-user
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By End-user, 2019-2024
4.5.3. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
4.5.3.1. Academic and Research Institutes
4.5.3.2. Biotechnology Companies
4.5.4. Market Attractiveness Analysis: End-user
5. Global Induced Pluripotent Stem Cells Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
5.3. Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Induced Pluripotent Stem Cells Market Outlook
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Service
6.2.3. By Application
6.2.4. By End-user
6.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Market Size (US$ Mn) Analysis and Forecast, By Cell Type, 2025-2032
6.4.1. Hepatocytes
6.4.2. Fibroblasts
6.4.3. Keratinocytes
6.4.4. Neurons
6.4.5. Others
6.5. Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
6.5.1. Drug Development
6.5.2. Regenerative Medicine
6.5.3. Toxicity Testing
6.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
6.6.1. Academic and Research Institutes
6.6.2. Biotechnology Companies
6.7. Market Attractiveness Analysis
7. Europe Induced Pluripotent Stem Cells Market Outlook
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Service
7.2.3. By Application
7.2.4. By End-user
7.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Market Size (US$ Mn) Analysis and Forecast, By Cell Type, 2025-2032
7.4.1. Hepatocytes
7.4.2. Fibroblasts
7.4.3. Keratinocytes
7.4.4. Neurons
7.4.5. Others
7.5. Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
7.5.1. Drug Development
7.5.2. Regenerative Medicine
7.5.3. Toxicity Testing
7.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
7.6.1. Academic and Research Institutes
7.6.2. Biotechnology Companies
7.7. Market Attractiveness Analysis
8. East Asia Induced Pluripotent Stem Cells Market Outlook
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Service
8.2.3. By Application
8.2.4. By End-user
8.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Market Size (US$ Mn) Analysis and Forecast, By Cell Type, 2025-2032
8.4.1. Hepatocytes
8.4.2. Fibroblasts
8.4.3. Keratinocytes
8.4.4. Neurons
8.4.5. Others
8.5. Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
8.5.1. Drug Development
8.5.2. Regenerative Medicine
8.5.3. Toxicity Testing
8.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
8.6.1. Academic and Research Institutes
8.6.2. Biotechnology Companies
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Induced Pluripotent Stem Cells Market Outlook
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Service
9.2.3. By Application
9.2.4. By End-user
9.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Market Size (US$ Mn) Analysis and Forecast, By Cell Type, 2025-2032
9.4.1. Hepatocytes
9.4.2. Fibroblasts
9.4.3. Keratinocytes
9.4.4. Neurons
9.4.5. Others
9.5. Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
9.5.1. Drug Development
9.5.2. Regenerative Medicine
9.5.3. Toxicity Testing
9.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
9.6.1. Academic and Research Institutes
9.6.2. Biotechnology Companies
9.7. Market Attractiveness Analysis
10. Latin America Induced Pluripotent Stem Cells Market Outlook
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Service
10.2.3. By Application
10.2.4. By End-user
10.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Market Size (US$ Mn) Analysis and Forecast, By Cell Type, 2025-2032
10.4.1. Hepatocytes
10.4.2. Fibroblasts
10.4.3. Keratinocytes
10.4.4. Neurons
10.4.5. Others
10.5. Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
10.5.1. Drug Development
10.5.2. Regenerative Medicine
10.5.3. Toxicity Testing
10.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
10.6.1. Academic and Research Institutes
10.6.2. Biotechnology Companies
10.7. Market Attractiveness Analysis
11. Middle East & Africa Induced Pluripotent Stem Cells Market Outlook
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Service
11.2.3. By Application
11.2.4. By End-user
11.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Market Size (US$ Mn) Analysis and Forecast, By Cell Type, 2025-2032
11.4.1. Hepatocytes
11.4.2. Fibroblasts
11.4.3. Keratinocytes
11.4.4. Neurons
11.4.5. Others
11.5. Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
11.5.1. Drug Development
11.5.2. Regenerative Medicine
11.5.3. Toxicity Testing
11.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
11.6.1. Academic and Research Institutes
11.6.2. Biotechnology Companies
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2024
12.2. Market Structure
12.2.1. Competition Intensity Mapping by Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Lonza Group AG
12.3.1.1. Overview
12.3.1.2. Segments and Cell Types
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Axol Bioscience Ltd.
12.3.3. Evotec
12.3.4. Hitachi, Ltd.
12.3.5. ViaCyte, Inc.
12.3.6. Merck KGaA
12.3.7. Takara Bio Inc.
12.3.8. REPROCELLS, Inc.
12.3.9. Fate Therapeutics
12.3.10. Thermo Fisher Scientific, Inc.
12.3.11. FUJIFILM Cellular Dynamics, Inc.
12.3.12. Applied StemCells, Inc.
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations